Amplia TherapeuticsASX:ATX 36 Quick Ratio is 19.79 as of Mar. 2026, which is 173% above its 10-year median of 7.26. GuruFocus rates ASX:ATX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Amplia Therapeutics ranks better than 92.09% on this metric.
Amplia Therapeutics has a quick ratio of 19.79. It generally indicates good short-term financial strength.
The historical rank and industry rank for Amplia Therapeutics's Quick Ratio or its related term are showing as below:
ASX:ATX'
s Quick Ratio Range Over the Past 10 Years
Min: 1.98 Med: 7.26 Max: 31.19
Current: 19.79
During the past 13 years, Amplia Therapeutics's highest Quick Ratio was 31.19. The lowest was 1.98. And the median was 7.26.
ASX:ATX's Quick Ratio is ranked better than 92.09% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs ASX:ATX: 19.79
Amplia Therapeutics (ASX:ATX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Amplia Therapeutics Quick Ratio Related Terms
Amplia Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Amplia Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ATX vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Amplia Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amplia Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Amplia Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Amplia Therapeutics's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amplia Therapeutics (ASX:ATX) has a Quick Ratio of 19.79 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Amplia Therapeutics and its competitors. This is 173% above median its historical median of 7.26. Over the past decade, Amplia Therapeutics' Quick Ratio has ranged from 1.98 to 31.19. According to the industry distribution chart, Amplia Therapeutics ranks #112 out of 1416 companies in the Biotechnology industry, placing it in the top 7.9%.
Is Amplia Therapeutics' Quick Ratio too high?
Amplia Therapeutics' current Quick Ratio of 19.79 is 173% above median its 10-year median of 7.26. Over the past 10 years, this metric has ranged from a low of 1.98 to a high of 31.19. The Biotechnology industry median Quick Ratio is 3.60. Amplia Therapeutics' value of 19.79 is 449.7% above this industry median. Based on the distribution chart, Amplia Therapeutics ranks #112 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Amplia Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Amplia Therapeutics ranks #112 out of 1416 companies for Quick Ratio. This places Amplia Therapeutics in the top 8% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Amplia Therapeutics' value of 19.79 is 449.7% above this benchmark. Historically, Amplia Therapeutics' own Quick Ratio has ranged from 1.98 to 31.19 over the past decade. While the company's 10-year median is 7.26 vs. the industry median of 3.60, Amplia Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amplia Therapeutics's current Quick Ratio of 19.79 is 449.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Amplia Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amplia Therapeutics's current Quick Ratio is 19.79, which is 173% above median its own 10-year median of 7.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current Quick Ratio of 19.79. The current Quick Ratio is 19.79, which is 173% above median its 10-year median of 7.26 and 449.7% above the Biotechnology industry median of 3.60. Amplia Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current Quick Ratio is 19.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
36GF Score
Get the complete analysis for ASX:ATX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ATX has been successfully added to your 
